Pfizer PAP India Downloads & RevenuePfizer PAP India · App Store
Not in any tracked top chart right now.
Updated 11 Nov 2026 · rankings refresh through the day
CategoryMedical
PriceFree
Released
Rating★ 4.5 (4)
Version3.1.0
Age rating12+
First seen by us
24 Oct 2026
24 Oct 2026Full timeline · 3 events
- 🆕Pfizer PAP India first spotted by AppInsiderIndia (found via developer)
- 📦Pfizer PAP India version 3.1.0To make our app better for you, we frequently update it. This release includes:
- Bug Fixes and Improvements - 🆕Pfizer PAP India released on the App Store
Collected from the stores by AppInsider since we first spotted the app. Dates are when we saw each change.
Rating
4.5 ★
4 ratings
Measured
Pfizer PAP India on the App Store
App details
App ID
6444154340
Publisher
TATA 1mg Healthcare Solutions Pvt Ltd
On the store since
Nov 2022
3 years on the store
Minimum OS
iOS 17.5+
iPhone XS and later
Devices
iPhone · iPad
Content rating
12+
1 content note below
Languages
1
EN
Size
2 MB
Also listed in
Health & Fitness
Content notesInfrequent/Mild Medical/Treatment Information
Where it ranks now
Every top chart it appears in across 30 countries.
| Country | Charts | Rank |
|---|---|---|
| Not charting right now. | ||
Ratings
App Store, worldwide.
Rating
4.5 ★
4 ratings
Measured
Ratings
4
Measured
About Pfizer PAP India
Patient Access Program (PAP), being implemented by MediAngels (Tata 1mg Technologies Pvt. Ltd.), and supported by Pfizer India Limited is a PAN India Program for Oncology drugs providing better access and facilitating either a partial or full subsidy on these drugs.
Currently there are 8 different PAPs available for oncology drugs (Dacoplice, Lorbriqua, Inonza, Palbace, Crizalk, Sutent, Inlyta, Aromasin and Campto). Each of these PAPs have various schemes available and depending upon the eligibility (as defined based on the indication for specific drugs) within the Program, patients may enroll themselves and avail the benefits of partial / full subsidy.
Patients are prescribed these drugs by HealthCare Practitioners (HCPs) based on their medical conditions and post that patients may choose to enroll into the PAP. Once the patients consent to enroll, the MediAngels team facilitates the enrollment process by requesting for basic information & documents including photo ID proof, address proof and prescription. Enrollment into the Program is governed by patient’s eligibility as per the indication(s) defined for the specific drug. Upon successful completion of enrollment, patients may select PAP scheme from the available options and submit invoices (paid purchase proofs) along with valid prescriptions to avail free drug assistance.
Currently there are 8 different PAPs available for oncology drugs (Dacoplice, Lorbriqua, Inonza, Palbace, Crizalk, Sutent, Inlyta, Aromasin and Campto). Each of these PAPs have various schemes available and depending upon the eligibility (as defined based on the indication for specific drugs) within the Program, patients may enroll themselves and avail the benefits of partial / full subsidy.
Patients are prescribed these drugs by HealthCare Practitioners (HCPs) based on their medical conditions and post that patients may choose to enroll into the PAP. Once the patients consent to enroll, the MediAngels team facilitates the enrollment process by requesting for basic information & documents including photo ID proof, address proof and prescription. Enrollment into the Program is governed by patient’s eligibility as per the indication(s) defined for the specific drug. Upon successful completion of enrollment, patients may select PAP scheme from the available options and submit invoices (paid purchase proofs) along with valid prescriptions to avail free drug assistance.
Latest updates
3.1.0
To make our app better for you, we frequently update it. This release includes:
- Bug Fixes and Improvements
